During institutional research on March 8, Kyodo Pharmaceutical said that the main business to be carried out jointly by Huahai, which was established by the company and Huahai Pharmaceutical, is the research, production, and sale of raw materials for high-end steroidal drugs. The planned construction project is divided into 2 phases, with a total of 13 high-end steroidal active ingredients. The company plans to use the construction of this joint venture to focus more on R&D, production and sales of steroidal drugs, provide richer upstream products for the steroidal drug industry chain and extend it to downstream products with high added value, and further improve the industrial chain.